China approves Haisco’s first‑in‑class oral therapy for PNH, expanding treatment options and signaling growth in domestic innovative drug pipeline
Executive summary: Haisco’s Ciprocopan Succinate Tablets received marketing approval from China’s NMPA for the treatment of paroxysmal nocturnal hemoglobinuria. The approval provides a new oral treatment option for PNH patients in China, potentially reducing reliance on costly infusions and validating Haisco’s innovative drug pipeline.
Who is involved: Haisco Pharmaceutical Group, National Medical Products Administration (NMPA), Patients with PNH in China
Likely next: Haisco will prepare for commercial launch, likely in Q4 2026, The company will seek inclusion in China’s national reimbursement list, Haisco may pursue additional indications or international filings for the compound
Haisco Pharmaceutical Group announced that its independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (HSK39297), received marketing approval from China’s National Medical Products Administration for the treatment of paroxysmal nocturnal hemoglobinuria. The approval marks the first domestically discovered oral agent for this rare blood disorder in China, offering an alternative to existing infusion‑based therapies. While the news validates Haisco’s R&D capabilities, commercial success will depend on pricing, reimbursement and uptake among physicians and patients.
Timeline
- — Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH (PR Newswire)
Analysis — what this means
Likely next events
- Haisco to initiate commercial launch of Ciprocopan Succinate Tablets in Q4 2026
- NMPA may consider adding the drug to the national reimbursement catalog by mid‑2027
- Competitors with oral PNH programs may accelerate clinical timelines in response
Sectors affected
- Pharmaceuticals
- Biotechnology
- Rare disease therapeutics
Regulatory implications
- NMPA’s Class 1 innovative drug designation grants priority review and possible tax incentives
- Post‑approval pharmacovigilance and safety reporting required under China’s drug safety regulations
- Pricing and reimbursement negotiations will involve the National Healthcare Security Administration
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped